Track topics on Twitter Track topics that are important to you
As part of the Biologics Price Competition and Innovation Act of 2009 within the Affordable Care Act, an abbreviated licensure pathway was developed for biologics that are “biosimilar” to or “interchangeable” with FDA-approved reference products, with the goal of increasing competition in the biologics market, reducing costs and expanding patient access to these therapies.While there are key differences between biosimilars and generic drugs, this pathway, although more rigorous, shares similarities with the development pathway for generics, according to Stephen B. Hanauer, MD, AGAF, FACG, the Clifford Joseph Barborka Professor of Medicine in the division of gastroenterology and hepatology at Northwestern University Feinberg School of Medicine.
Original Article: Path to approval: How biosimilars are developed, approved in the USNEXT ARTICLE
The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...